PUMA BIOTECHNOLOGY, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $56.5M | — | $44.8M | — | — | — | $54.5M |
| Cost of Revenue | — | $12.5M | — | $10.4M | — | — | — | $12.2M |
| Gross Profit | — | $44.0M | — | $34.4M | — | — | — | $42.3M |
| Gross Margin | — | 77.9% | — | 76.7% | — | — | — | 77.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $17.5M | — | $18.4M | — | — | — | $16.8M |
| Operating Income | — | $7.6M | — | $-3.8M | — | — | — | $9.6M |
| Operating Margin | — | 13.4% | — | -8.5% | — | — | — | 17.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $8.2M | — | $-3.4M | — | — | — | $9.2M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $8.2M | — | $-3.8M | — | — | — | $8.8M |
| Net Margin | — | 14.5% | — | -8.4% | — | — | — | 16.2% |
| EPS (Basic) | — | $0.16 | — | $-0.07 | — | — | — | $0.18 |
| EPS (Diluted) | — | $0.16 | — | $-0.07 | — | — | — | $0.17 |
| Shares Outstanding (Basic) | 51.6M | 50.9M | 50.9M | 50.8M | 50.9M | 50.4M | 50.4M | 50.3M |
| Shares Outstanding (Diluted) | 51.6M | 52.6M | 50.9M | 50.8M | 50.9M | 50.4M | 50.4M | 50.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |